Granted Patent
B2
US 12,453,709 · App. 18/305,826 · Granted Oct 28, 2025
Compositions and methods for treating autism
Assignee:
YAMO PHARMACEUTICALS LLC
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention provides compositions and methods of treating autism. Specifically, the invention relates to treating the core symptoms of autism by administering α-methyl-DL-tyrosine.
Claims (22)
1. A method for treating a disorder that is Asperger's Disorder (Asperger Syndrome) or Social Communication Disorder in a human in need thereof, comprising:
administering a daily amount of about 50 mg (w/w) to about 1500 mg (w/w) of α-methyl-DL-tyrosine for a term of at least one week.
2. The method of claim 1 , further comprising administering to the human an effective amount of a beta adrenergic agonist for a term of at least one week.
3. The method of claim 2 , wherein beta adrenergic agonist is albuterol, levalbuterol, fenoterol, formoterol, isoproterenol, metaproterenol, salmeterol, terbutaline, clenbuterol, isoetarine, pirbuterol, procaterol, ritodrine, epinephrine, or combinations thereof.
4. The method of claim 1 , wherein the disorder is Asperger's Disorder.
5. The method of claim 1 , wherein the disorder is Social Communication Disorder.
6. The method of claim 1 , wherein the daily amount of α-methyl-DL-tyrosine administered to the human is about 100 mg.
7. The method of claim 1 , wherein the daily amount of α-methyl-DL-tyrosine administered to the human is about 200 mg.
8. The method of claim 1 , wherein the daily amount of α-methyl-DL-tyrosine administered to the human is about 250 mg.
9. The method of claim 1 , wherein the daily amount of α-methyl-DL-tyrosine administered to the human is about 300 mg.
10. The method of claim 1 , wherein the daily amount of α-methyl-DL-tyrosine administered to the human is about 350 mg.
11. The method of claim 1 , wherein the daily amount of α-methyl-DL-tyrosine is administered in divided doses.
12. The method of claim 11 , wherein the daily amount of α-methyl-DL-tyrosine is administered in two doses.
13. The method of claim 11 , wherein the daily amount of α-methyl-DL-tyrosine is administered in three doses.
14. The method of claim 1 , wherein the term is from about 1 week to about 4 weeks.
15. The method of claim 1 , wherein the term is more than 4 weeks.
16. The method of claim 1 , wherein the term is at least 12 weeks.
17. The method of claim 1 , wherein the administration results in a change from baseline on the Vineland Adaptive Behavior Scales-3rd Edition (VABS-3).
18. The method of claim 1 , wherein the α-methyl-DL-tyrosine and beta adrenergic agonist are administered simultaneously.
19. A method for treating a disorder that is Asperger's Disorder in a human in need thereof, comprising administering to the human 200 mg to 300 mg of α-methyl-DL-tyrosine twice daily for a term of 12 weeks.
20. The method of claim 19 , further comprising administering an effective amount of a beta adrenergic agonist to the human for a term of 12 weeks.
21. The method of claim 19 , wherein the administration results in a change from baseline on the Vineland Adaptive Behavior Scales-3rd Edition (VABS-3).
Continuity (8)
Provisional Application
61894261
· Oct 22, 2013
References Cited (103)
US 4117161A
· Pozuelo
· 1978
[cited by applicant]
US 4160835A
· Stone
· 1979
[cited by applicant]
US 4165382A
· Pozuelo
· 1979
[cited by applicant]
US 4189604A
· Umezawa et al.
· 1980
[cited by applicant]
US 4240975A
· Umezawa et al.
· 1980
[cited by applicant]
US 5073541A
· Taylor et al.
· 1991
[cited by applicant]
US 5206018A
· Sehgal et al.
· 1993
[cited by applicant]
US 5225435A
· Pawelek et al.
· 1993
[cited by applicant]
US 5576290A
· Hadley
· 1996
[cited by applicant]
US 5674839A
· Hruby et al.
· 1997
[cited by applicant]
US 5683981A
· Hadley et al.
· 1997
[cited by applicant]
US 5714576A
· Hruby et al.
· 1998
[cited by applicant]
US 6359001B1
· Drago
· 2002
[cited by applicant]
US 7452868B2
· Kuzma et al.
· 2008
[cited by applicant]
US 8003689B2
· Veverka
· 2011
[cited by applicant]
US 8481498B1
· Hoffman
· 2013
[cited by applicant]
US 9308188B2
· Hoffman
· 2016
[cited by applicant]
US 9326962B2
· Hoffman
· 2016
[cited by applicant]
US 9757348B2
· Hoffman
· 2017
[cited by applicant]
US 9763903B2
· Hoffman
· 2017
[cited by applicant]
US 20020128304A1
· D'Amato
· 2002
[cited by applicant]
US 20030059471A1
· Compton et al.
· 2003
[cited by applicant]
US 20060122181A1
· Ikemoto et al.
· 2006
[cited by applicant]
US 20090030067A1
· Wosikowski-Buters et al.
· 2009
[cited by applicant]
US 20130183263A1
· Hoffman
· 2013
[cited by applicant]
US 20130184214A1
· Hoffman
· 2013
[cited by applicant]
US 20150111878A1
· Hoffman
· 2015
[cited by applicant]
JP S54062325A
· 1979
[cited by applicant]
JP 2008515801A
· 2008
[cited by applicant]
WO WO1999056747A1
· 1999
[cited by applicant]
WO WO2001078704A2
· 2001
[cited by applicant]
WO WO2002100885A2
· 2002
[cited by applicant]
WO WO2009054001A1
· 2009
[cited by applicant]
WO WO2009109649A1
· 2009
[cited by applicant]
WO WO2009131631A1
· 2009
[cited by applicant]
WO WO2010022243A1
· 2010
[cited by applicant]
WO WO2010118419A2
· 2010
[cited by applicant]
WO WO2011112576A1
· 2011
[cited by applicant]
WO WO2012123819A1
· 2012
[cited by applicant]
WO WO2012165984A1
· 2012
[cited by applicant]
WO WO2013061161A2
· 2013
[cited by applicant]
WO WO2013103746A1
· 2013
[cited by applicant]
WO WO2015061328A2
· 2015
[cited by applicant]
WO WO2016167944A2
· 2016
[cited by applicant]
Odenwald et al., “Intestinal Permeability Defects: Is It Time to Treat?” Advances in Translational Science, Clinical Gastroenterology and Hepatology, vol. 11, No. 9, Sep. 2013, pp. 1075-1083.
[cited by applicant]
Demser, 1979 [Cited in related U.S. Appl. No. 16/040,405].
[cited by applicant]
Demserdose, 1979 [Cited in related U.S. Appl. No. 16/040,405].
[cited by applicant]
Cools. A.R. Cas: 77: 96941, 1972 [Cited in related U.S. Appl. No. 16/040,405].
[cited by applicant]
Pasca et al. 2011, Nature medicine, 17(12); 1657-1662 [Cited in related U.S. Appl. No. 16/040,405].
[cited by applicant]
Kato, “Intestinal First-Pass Metabolism of CYP3A4 Substrates” Drug Metab. Pharmacokinet., vol. 23, No. 2, pp. 87-94, 2008 [Cited in related U.S. Appl. No. 16/040,405].
[cited by applicant]
Bloemen et al., “Challenge and Therapeutic Studies Using Alpha-Methyl-para-Tyrosine (AMPT) in Neuropsychiatric Disorders: A Review,” Central Nervous System Agents in Medicinal Chemistry, 8(4), Dec. 2008, 249-56 [Cited i…
[cited by applicant]
Boni et al., “Radioiodine-labelled Alpha-methyl-tyrosine in Malignant Melanoma: Cell Culture Studies and Results in Patients,” British Journal of Dermatology, Jul. 1997, 137(1), 96-100 [Cited in related U.S. Appl. No. 1…
[cited by applicant]
Brogden et al., “Alpha-Methyl-p-tyrosine: A Review of its Pharmacology and Clinical Use,” Drugs, Feb. 1981, 21(2), 81-89 [Cited in related U.S. Appl. No. 14/062,165].
[cited by applicant]
Cabrera Lopez et al., “Effects of Rapamycin on Angiomyolipomas in Patients with Tuberous Sclerosis,” Nefrologia, Apr. 2011, 31(3), 292-98 [Cited in related U.S. Appl. No. 14/062, 165].
[cited by applicant]
Chen et al., “Progress in the Development of Bestatin Analogues as Aminopeptidases Inhibitors,” Current Medical Chemistry, Mar. 2011, 8(7), 964-76 [Cited in related U.S. Appl. No. 14/062,165].
[cited by applicant]
Chhun et al., “7. The Cytochrome P-450 2C9/2019 but Not the ABCB1 Genetic Polymorphism May Be Associated With the Liver Cytochrome 3A4 Induction by Phenytoin.” Journal of Clinical Psychopharmacology, Jun. 2012, 32(3), 4…
[cited by applicant]
Chlu et al., “Lipid-Based Nanoparticulate Systems for the Delivery of Anti-Cancer Drug Cocktails: Implications on Pharmacokinetics and Drug Toxicities,” Current Drug Metabolism, 2009,10, 861-74 [Cited in related U.S. Ap…
[cited by applicant]
De Kort et al., “Leaky Gut and Diabetes Mellitus: What is the Link” Obesity Reviews, 2011, 12,449-58 [Cited in related U.S. Appl. No. 14/062,165].
[cited by applicant]
Dorr et al., “Evaluation of Melanotan-II, A Superpotent Cyclic Melanotropic Peptide in a Pilot Phase-I Clinical Study,” Life Sciences, Apr. 1996, 58(20), 1777-84 [Cited in related U.S. Appl. No. 14/062,165].
[cited by applicant]
Ell, “Brain Tumor Uptake of lodo-alpha-methyl-tyrosine,” Journal of Nuclear Medicine, Nov. 1991, 32(11), 2193-94 [Cited in related U.S. Appl. No. 14/062,165].
[cited by applicant]
Espeillac et al., “S6 Kinase 1 is Required for Rapamycin-sensitive Liver Proliferation After Mouse Hepatectomy,” The Journal of Clinical Investigation, Jul. 2011, 121(7), 2821-32 [Cited in related U.S. Appl. No. 14/062,…
[cited by applicant]
Fan et al., “Impact of System L Amino Acid Transporter 1 (LAT1) on Proliferation of Human Ovarian Cancer Cells: A Possible Target for Combination Therapy with Anti-Proliferative Aminopeptidase Inhibitors,” Biochemical P…
[cited by applicant]
Fitzgerald et al., “Effect of Melanotan, [Nle(4). D-Phe(7)]-alpha-MSH, on Melanin Synthesis in Humans with MC1 R Variant Alleles,” Peptides, Feb. 2006, 27(2), 388-94 [Cited in related U.S. Appl. No. 14/062,165].
[cited by applicant]
Fujimori et al., Mechanisms of Hyperglycernic Response to Chlorpromazine Administered into Lateral Ventricle in Rats-I, Possible Role of Dopaminergic Nervous System, Neuropharmacology, Pergamon Press, Oxford, 13(4), Apr…
[cited by applicant]
Ichimura et al., “Immunohistochemical Expression of Aminopeptidase N (CD13) in Human Lung Squamous Cell Carcinomas, with Special Reference to Bestatin Adjuvant Therapy,” Pathology International, Jun. 2006, 56(6), 296-30…
[cited by applicant]
Kargiotis et al., “Epilepsy in the Cancer Patient,” Cancer Chemotherapy and Pharmacology, Mar. 2011, 67(3), 489-501 [Cited in related U.S. Appl. No. 14/062,165].
[cited by applicant]
Krige et al., “CHR-2797: An Antiproliferative Aminopeptidase Inhibitor that Leads to Amino Acid Deprivation in Human Leukemic Cells,” Cancer Research, Aug. 15, 2008, 68(16), 6669-79 [Cited in related U.S. Appl. No. 14/0…
[cited by applicant]
Kulke et al., “Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting,” Journal of Clinical Oncology, Mar. 20…
[cited by applicant]
Landmark, “Antiepileptic Drugs in Non-Epilepsy Disorders—Relations Between Mechanisms of Action and Clinical Efficacy,” CNS Drugs, 2008, 22(1), 27-47 [Cited in related U.S. Appl. No. 14/062,165].
[cited by applicant]
Liu et al., “Combinatorial Effects of Lapatinib and Rapamycin in Triple-Negative Breast Cancer Cells,” Molecular Dancer Therapeutics, Aug. 2011, 10, 1460-69 [Cited in related U.S. Appl. No. 14/062,165].
[cited by applicant]
Longhurst et al., “Effects of Catecholamine Depletion with AMPT (alpha-methyl-para-tyrosine) in Obsessive-Compulsive Disorder,” Biological Psychiatry, Elsevier Science, NY, 46(4), Aug. 1999, 573-76 [Cited in related U.S…
[cited by applicant]
Longo et al., “Efficacy and Tolerability of Long-Acting Octreotide in the Treatment of Thymic Tumors: Results of a Pilot Trial,” American Journal of Clinical Oncology, Apr. 2012, 35(2). 105-09 [Cited in related U.S. App…
[cited by applicant]
Nakagami, “A Case of Malignant Pheochromocytoma Treated with 1311-metalodobenzylguanidine and alpha-methyl-o-tyrosine,” Japanese Journal of Medicine, May-Jun. 1990, 29(3), 329-33 [Cited in related U.S. Appl. No. 14/062,…
[cited by applicant]
Oberman, Lindsay, “mGluR Antagonists and GABA Agonists as Novel Pharmacological Agents for the Treatment of Autism Spectrum Disorders,” Expert Opinion on Investigational Drugs, 2012, 21(12): 1819-1825 [Cited in related …
[cited by applicant]
Ram et al., “Failure of alpha-methyltyrosine to Prevent Hypertensive Crisis in Pheochromocytoma,” Archives of Internal Medicine, Nov. 1985, 145(11), 2114-15 [Cited in related U.S. Appl. No. 14/062,165].
[cited by applicant]
Russo, “Correlation Between Hepatocyte Growth Factor (HGF) and Gamma-Aminobutyric Acid (GABA) Plasma Levels in Autistic Children,” Biomarker Insights, Jun. 1, 2013, 69-75 [Cited in related U.S. Appl. No. 15/138,733].
[cited by applicant]
Ryakhovsky et al., “The First Preparative Solution Phase Synthesis of Melanotan II,” Beilstein Journal of Organic Chemistry, 2008, 4, 1-6 [Cited in related U.S. Appl. No. 14/062,165].
[cited by applicant]
Standards of Medical Care in Diabetes—2013, American Diabetes Association, Jan. 2013. vol. 36, Supp. 1, S11-866 [Cited in related U.S. Appl. No. 14/062,165].
[cited by applicant]
Steinsapir et al., “Metyrosine and Pheochromocytoma,” Archives of Internal Medicine, Apr. 1997, 157(8), 901-06 [Cited in related U.S. Appl. No. 14/062,165].
[cited by applicant]
Tada et al., “Three Cases of Malignant Pheochromocytoma Treated with Cyclophosphamide, Vincristine, and Dacarbazine Combination Chemotherapy and alpha-methyl-p-tyrosine to Control Hypercatecholaminemia,” Hormone Researc…
[cited by applicant]
Taveria-Dasilva et al., “Sirolimus Therapy in Patients with Lymphangioleiomyomatosis,” Summaries for Patients, Annals of Internal Medicine, Jun. 21, 2011, 154(12), 144 [Cited in related U.S. Appl. No. 14/062,165].
[cited by applicant]
Terauchi et al., “Inhibition of APN/CD 13 Leads to Suppressed Progressive Potential in Ovarian Carcinoma Cells,” BMC Cancer, 2007, 7, 1-12 [Cited in related U.S. Appl. No. 14/062,165].
[cited by applicant]
Tsukamoto et al., “Aminopeptidase N (APN)/CD13 Inhibitor, Ubenimex, Enhances Radiation Sensitivity in Human Cervical Cancer,” BMC Cancer, Mar. 2008, 8:74, 8 pages [Cited in related U.S. Appl. No. 14/062,165].
[cited by applicant]
“Tyrosine Derivatives for Sale,” Sigma-Aldrich, 2012, 1 page [Cited in related U.S. Appl. No. 14/520,116].
[cited by applicant]
Voorhess, “Effect of alpha-methyl-p-tyrosine on 3,4-dihydroxyphenylalanine (DOPA) Excretion of Hamsters with Melanotic Melanoma,” Cancer Research, Mar. 1968, 28, 452-54 [Cited in related U.S. Appl. No. 14/062,165].
[cited by applicant]
Yamada et al., “Involvement of Adrenaline in Diazepam-Induced Hyperglycemia in Mice,” Life Sciences, Pergarmon Press, Oxford, 66(13), Feb. 18, 2000, 1213-21 [Cited in related U.S. Appl. No. 15/695,327].
[cited by applicant]
Zimmermann et al., “Prolonged Inhibition of Presynaptic Catecholamine Synthesis With a-Methyl-Para-Tyrosine Attenuates the Circadian Rhythm of Human TSH Secretion,” J. Soc. Gynecol Investing, May/Jun. 2001, 8(3), 174-78…
[cited by applicant]
Ziying et al., “Observation of Cabamazepine Treating Painful Diabetic Neuropathy,” Medical Recapitulate, 15(8), Apr. 30, 2009, 1270-71 [Cited in related U.S. Appl. No. 15/695,327].
[cited by applicant]
He et al., “Cytoplasm-predominant Pten associates with increased region-specific brain tyrosine hydroxylase and lopamine D2 receptors in mouse model with autistic traits” Molecular Autism, vol. 6, No. 63,2015, 10 Pages …
[cited by applicant]
Sumida et al., Jpn J. Clin. Pharmacol. Ther., vol. 31, No. 2, Mar. 2000, pp. 305-306 [Cited in related U.S. Appl. No. 16/040,405].
[cited by applicant]
Lai et al.; The Lancet; vol. 383 No. 9920; Mar. 2014; p. 896-910 (contains Summary).
[cited by applicant]